Cancer stem cells have been proposed to be important for initiation, maintenance and recurrence of various malignancies, including acute myeloid leukemia (AML) 1-3 . We have previously reported 4 that CD34 + CD38 − human primary AML stem cells residing in the endosteal region of the bone marrow are relatively chemotherapy resistant. Using a NOD/SCID/IL2r null mouse model of human AML, we now show that the AML stem cells in the endosteal region are cell cycle quiescent and that these stem cells can be induced to enter the cell cycle by treatment with granulocyte colony-stimulating factor (G-CSF). In combination with cell cycle-dependent chemotherapy, G-CSF treatment significantly enhances induction of apoptosis and elimination of human primary AML stem cells in vivo. The combination therapy leads to significantly increased survival of secondary recipients after transplantation of leukemia cells compared with chemotherapy alone.
Despite increasing understanding of the pathogenesis and biology of AML, patient outcomes remain poor, with a median survival of ~1 year with standard treatment due to high rates of disease relapse 5 . Recent studies have demonstrated that leukemia stem cells (LSCs) play a central role in AML pathogenesis, suggesting that failure to eradicate these cells is an important factor in patient outcomes 6 . Resembling normal hematopoietic stem cells (HSCs) in their ability to engraft and to produce progeny and self-renew continuously in vivo 7 , AML stem cells home to the endosteal region of the bone marrow, where they are resistant to chemotherapy. In addition, an enrichment of AML stem cells in the G0 phase of cell cycle suggests cell cycle quiescence as a mechanism of their chemotherapy resistance. Therefore, we aimed to determine the role of cell cycle status in chemotherapy resistance of AML stem cells and to develop a therapeutic strategy against LSCs by functionally modifying them in vivo.
We generated mouse models of human AML by engrafting newborn nonobese diabetic/severe combined immunodeficient/interleukin (NOD/SCID/IL) 2rγ null mice with purified human (h)CD34 + CD38 − LSCs from seven AML patients. The mean peripheral blood and bone marrow hCD45 + cell engraftment levels of recipients were 77.6 ± 5.9% and 95.0 ± 1.8% (mean ± s.e.m., n = 48), respectively, indicating that the recipient bone marrow was nearly completely replaced by human AML cells. Flow cytometry plots of bone marrow from representative recipients engrafted with cells from each case of AML are shown in Figure 1a (cases 3 and 5) and Supplementary Figure 1a (cases 1, 2, 4, 6 and 7). All hCD45 + cells in the recipient peripheral blood and bone marrow were also hCD33 + , indicating that all CD45 + human hematopoietic cells in these recipients are human AML cells (Supplementary Fig. 1b ). The injection of purified hCD34 + CD38 − cells resulted in repopulation of recipient bone marrow with hCD34 + hCD38 − , hCD34 + CD38 + and hCD34 − cells ( Fig. 1a and Supplementary Fig. 1c ). Successful secondary engraftment ( Supplementary Fig. 1d ) demonstrated the self-renewal capacity of hCD34 + hCD38 − cells, thereby satisfying the criteria for malignant stem cells (long-term engraftment capacity, capacity to develop leukemia in vivo, the generation of non-stem AML cells and self-renewal capacity). Although there was case-dependent variability, the majority of recipient bone marrow LSCs was in G0 and G0/G1 phases of the cell cycle. The frequency of cells in G0 and G0/G1 was significantly higher in the hCD34 + CD38 − than in the hCD34 + CD38 + population (Supplementary Table 1) .
Next we examined the relationship between LSC cell cycle status and the cytotoxic effect of the chemotherapeutic agent cytosine arabinoside (Ara-C), a key chemotherapeutic agent used both in remission induction and post-remission therapy for AML patients. Mean pretreatment peripheral blood engraftment level as measured by percent hCD45 + cells was similar between Ara-C-treated and control AML-engrafted recipients (74.9 ± 4.2% and 67.6 ± 7.1%, respectively, n = 15 for each group, P = 0.4041 by two-tailed t-test). Representative cell cycle analyses after BrdU incorporation are shown in Supplementary Figure 1e . When the AML-engrafted mice were given Ara-C, bone marrow CD34 + CD38 − AML cells in the S-phase of the cell cycle were preferentially eliminated (S = 0.1 ± 0.1% in Ara-C-treated group and S = 10.6 ± 0.9% in control group, respectively, n = 15 for each group, P < 0.0001 by two-tailed t-test). This was accompanied by the enrichment of quiescent LSCs in the G0/G1 phases of the cell cycle (G0/G1 = 91.7 ± 2.3% in the Ara-C-treated group and G0/G1 = 80.9 ± 1.5% in controls, n = 15 for each group, l e t t e r s P = 0.0011 by two-tailed t-test). These findings demonstrate that within hCD34 + CD38 − LSC population, cell cycle quiescence is associated with Ara-C resistance.
Therefore, we hypothesized that entry of quiescent LSCs into the cell cycle would increase their susceptibility to chemotherapeutic agents. To test this hypothesis, we examined whether granulocyte colonystimulating factor (G-CSF) induces human LSCs to enter the cell cycle in vivo. Although induction of human and mouse normal HSC cell cycle entry by G-CSF has been described, the effect of G-CSF on LSCs has not been investigated 8, 9 . Hoechst/PyroninY (Fig. 1a,b) and BrdU incorporation (Supplementary Fig. 1e ) assays were used to measure the induction of the cell cycle in LSCs. In all seven primary AML cases, the LSCs in the bone marrow of AML-engrafted recipients treated with 300 µg/kg G-CSF daily for 5 d showed a significant (P values in legend to Fig. 1 ) reduction in the fraction of cells in G0 phase with a concomitant increase of LSCs in S and G2/M phases (Fig. 1c) .
We have previously demonstrated that chemotherapy-resistant CD34 + CD38 − LSCs are enriched within the bone marrow endosteal region, whereas CD38 + AML cells resided mainly in the central region of the bone marrow 4 . Therefore, we performed Ki67 labeling in primary human AML-engrafted recipient bone sections to directly examine the cell cycle status of LSCs within the bone marrow endosteal region, adjacent to the bone endosteum lined with osteopontin-positive osteoblasts (Supplementary Fig. 2 ). Ki67 is a nuclear protein expressed in proliferating cells during late G1, S, G2 and M phases but not in quiescent cells in the G0 phase of the cell cycle. Figure 2 shows bone sections from a representative AML-engrafted recipient at steady state and after G-CSF treatment. In an untreated recipient, recipient (bone marrow human AML chimerism of 98.5%) human leukemic cells in the central zone of the bone marrow were strongly Ki67 + , indicating that they are highly proliferative, whereas the majority of AML cells abutting the endosteum were in G0 phase as evidenced by the negative Ki67 labeling (Fig. 2a,b) . AML cells in the perivascular region-one of the physiological niches for normal murine HSCs 10,11 -were actively cycling as demonstrated by Ki67 + staining (Fig. 2d,e) . Z-stack images showing vertical slices of the bone section further confirmed the relative paucity of Ki67 + cells in the region adjacent to the endosteum (Fig. 2c,f) . This endosteal enrichment of G0 AML cells combined with our previous observation that chemotherapy-resistant LSCs preferentially localize within the bone marrow endosteal region suggest that AML relapse may be attributable to cell cycle quiescence within the bone marrow niche.
We then examined whether in vivo cytokine treatment induces quiescent LSCs within the endosteal niche to enter the cell cycle. (Fig. 2g-i) . The central zone of the bone marrow from the same recipient also had numerous Ki67 + CD45 + human AML cells (Supplementary Fig. 3a-c) . Three-dimensional reconstruction of the bone section clearly demonstrated cell cycle entry by human CD45 + AML cells within the endosteal region after cytokine treatment (Fig. 2j,k and Supplementary Movies 1 and 2) . A great majority of bone marrow cells in the AML-engrafted recipients examined were hCD45 + CD33 + AML cells (93.2 ± 1.3% for G-CSF-treated group, n = 37; 96.2 ± 0.6% for control group, n = 45). Co-labeling for human CD34 and Ki67 demonstrated that human CD34 + AML cells in the endosteal region enter the cell cycle in response to in vivo cytokine treatment ( Supplementary Fig. 3d,e,g,h) . The results of BrdU staining were consistent with Ki67 labeling, showing cell cycle induction of human AML cells within the endosteal region in cytokine-treated recipients Number of control and experimental (G-CSF) recipients, respectively, from AML case 1 (n = 7, n = 6, P = 0.0010); case 2 (n = 9, n = 6, P < 0.0001); case 3 (n = 10, n = 5, P < 0.0001); case 4 (n = 6, n = 4, P = 0.0016); case 5 (n = 5, n = 6, P = 0.0043); case 6 (n = 5, n = 5, P = 0.0050); case 7 (n = 3, n = 5, P = 0.0004); each by two-tailed t-test. l e t t e r s (Supplementary Fig. 3f,i) . Quantification of human CD45 + Ki67 + cells within the endosteal region demonstrated a statistically significant increase (P < 0.0001) in cycling LSCs after in vivo cytokine treatment (Supplementary Table 2 ). Taken together, these findings indicate that in vivo administration of G-CSF induces quiescent LSCs residing within the endosteal niche to enter the cell cycle.
Next, to demonstrate that cell cycle entry increases the susceptibility of human LSCs to chemotherapy in vivo, we developed an in vivo treatment model using AML-engrafted recipients. The recipients received either Ara-C 1 g/kg daily for 2 d or G-CSF 300 µg/kg daily for 5 d combined with Ara-C 1g/kg daily on days 4 and 5. After chemotherapy (Ara-C) alone or chemotherapy following cell cycle induction by G-CSF, the recipient bone marrow was evaluated through (i) flow cytometric assessment of LSC apoptosis as evidenced by active caspase 3 expression, (ii) histological examination of bone marrow in situ to directly examine LSC apoptosis within the bone marrow niche by TUNEL staining and (iii) functional determination of the frequency and AML-initiating capacity of the remaining LSCs by limiting-dilution serial transplantation.
Mean pretreatment human AML engraftment as measured by percent of peripheral blood hCD45 + cells was similar between groups receiving chemotherapy alone and chemotherapy with cell cycle induction (31.6 ± 4.1% with a range of 10.6-67.5% and 28.5 ± 4.3% with a range of 9.9-78.4%, respectively, P = 0.6031 by two-tailed t-test).
The degree of apoptosis in LSCs was quantified by flow cytometric measurement of active caspase 3 expression within bone marrow CD34 + CD38 − cells (Fig. 3a and Supplementary Fig. 4 ). Chemotherapy with cell cycle induction significantly (P values in legend to Fig. 3 ) reduced the frequency of viable nonapoptotic hCD34 + CD38 − LSCs in recipients engrafted with AML originating from each of the seven primary AML cases examined. Although this effect is variable among the seven AML cases reflecting biological heterogeneity, it is statistically significant in each case.
In situ examination of the bone marrow demonstrated that in recipients treated with chemotherapy alone, TUNEL-negative viable AML cells remained at the endosteum (Fig. 3b, upper panels) . In contrast, chemotherapy with cell cycle induction resulted in increased apoptosis in the endosteal region (as well as the central region), as evidenced l e t t e r s (Fig. 3b, lower panels) . After treatment, a large majority of the bone marrow cells was hCD45 + CD33 + (95.9 ± 0.8% for chemotherapy alone, n = 32; 91.4 ± 1.3% for chemotherapy with cell cycle induction, n = 29). Therefore, the majority of the cells present in the histological sections shown are human AML cells, not residual mouse hematopoietic cells. Taken together, these findings indicate that chemotherapy-induced LSC apoptosis within the endosteal niche is enhanced by cell cycle induction of LSCs in vivo.
We found significant reductions in both the proportion and number of viable hCD34 + cells in the bone marrow of recipients after chemotherapy with cell cycle induction with the absolute number of hCD34 + bone marrow cells decreasing 1.5-to sevenfold compared with those receiving chemotherapy alone (Supplementary Table 3) . Although the reduction in hCD34 + cells indirectly demonstrates the reduction of LSC frequency and number, in vivo evaluation of AML initiation is required to definitively prove the reduction in LSC frequency and function. Therefore, we carried out limiting-dilution serial transplantation of purified viable bone marrow hCD34 + cells, at doses of 2 × 10 2 , 2 × 10 3 , 2 × 10 4 and 2 × 10 5 cells per mouse, the mice being AML-engrafted recipients treated with either chemotherapy alone or chemotherapy with cell cycle induction. CD34 + cells, not CD34 + CD38 − cells, were used as the graft for serial transplantation given the possibility that the CD38 expression level may alter with exposure to G-CSF. Peripheral blood engraftment time course and overall engraftment efficiency of serial transplant recipients at each human CD34 + LSC graft dose are shown in Figure 3c and Supplementary Table 4 . At the graft dose of 200 cells, none of the 18 recipients of LSCs from cytokine combined with Ara-C-treated AML-engrafted mice developed AML at 24 weeks post-transplantation. In contrast, 13/18 (72.2%) recipients of 200 LSCs from Ara-C onlytreated AML-engrafted mice developed AML. At the dose of 2 × 10 4 and 2 × 10 5 , all recipients of LSCs from Ara-C only-treated AML-engrafted recipients developed AML by week 24 (n = 38 and n = 14, respectively) whereas only 15/31 and 10/15 recipients of LSCs from G-CSF+Ara-Ctreated AML-engrafted mice developed AML. Although the engraftment kinetics varied among LSC samples, at each dose level, the frequency of recipient mice not developing AML was significantly (P < 0.0001) higher in the group treated with G-CSF followed by Ara-C compared with the group treated with Ara-C alone (Fig. 3c and Supplementary  Table 4 ). The frequency of LSCs was estimated by Poisson statistics using the method of maximum likelihood, a standard methodology used in the estimation of HSC frequencies in limiting-dilution transplantation assay 12, 13 . Estimated LSC frequency within bone marrow hCD34 + cells was significantly lower in the recipients after chemotherapy with cell cycle induction (Supplementary Table 5 , overall frequencies 1 in 55,076 versus 1 in 560, P = 0.0001 by two-tailed t-test). Furthermore, 24 weeks after transplantation, 7.2% (9 out of 125) of recipients of bone marrow hCD34 + cells from AML-engrafted recipients treated with chemotherapy alone survived whereas 74.3% (81 out of 109) of the recipients of bone marrow hCD34 + cells from AML-engrafted recipients exposed to cytokine before chemotherapy survived (Fig. 3d) . Taken together, these findings indicate that in vivo cell cycle entry potentiates the elimination of chemotherapy-resistant human LSCs. Although increased elimination of LSCs correlated with increased long-term survival of the serial transplantation recipients, it was not possible to directly assess the long-term survival of in vivo-treated recipients, owing to the inherent toxicity of the treatments leading to severe complications and frequent death of the recipients shortly after treatment.
Our data demonstrate that primary AML LSCs are cell cycle quiescent within the endosteal niche of the bone marrow of a newborn NOD/SCID/IL2rγ null xenotransplantation model. These quiescent LSCs within the bone marrow endosteal region survive in vivo chemotherapy despite efficient elimination of cycling AML cells, consistent with the gap between successful remission induction and overall survival in AML. Furthermore, cell cycle quiescence of human AML LSCs can be modified by in vivo G-CSF administration, leading to substantially enhanced chemotherapy sensitivity of human AML LSCs in vivo. These findings provide proof of concept that cell cycle inducers such as G-CSF can directly modify the functional behavior of LSCs in vivo, increasing their responsiveness to chemotherapy (Fig. 3e,f) .
The role of G-CSF as an inducer of myeloid maturation, differentiation and proliferation has been successfully exploited to accelerate granulocyte recovery in the setting of myelosuppressive chemotherapy and its function as a mobilizer of HSCs has proven effective for the collection of peripheral blood hematopoietic stem cells 14 . G-CSF was also found to metabolically activate AML and chronic myelogenous leukemia (CML) cells, enhancing the effects of chemotherapy in vitro. This observation led to clinical studies examining G-CSF during induction chemotherapy for AML 15, 16 . Statistically significant improvements in the rate of relapse and disease-free survival at 4 years in all patients was reported in a large, randomized, controlled study of 640 newly diagnosed AML patients 17 . Subsequently, five other randomized, controlled studies examining the addition of G-CSF during induction chemotherapy reported equivocal results [18] [19] [20] [21] [22] . The effects of cytokinecombined chemotherapy on LSCs were unevaluated in these studies.
It is difficult to interpret the results of these studies as a composite because of different the treatment regimens and patient populations. Two studies evaluate treatment efficacy in relapsed/refractory patients whereas three trials comprised elderly patients. LSC-targeted therapy is unlikely to affect the rates of remission induction substantially, as LSCs are not expected to constitute a substantial portion of the total body AML burden at the time of induction. Therefore, LSC-targeted therapy likely has the greatest positive impact in the setting of post-remission therapy, whether as a part of consolidation therapy or as pretransplant conditioning. This is consistent with uncontrolled single-center experiences reporting improved patient outcomes associated with pretransplant conditioning regimen containing G-CSF 23, 24 .
We observed considerable variability in the response of LSCs to cell cycle induction and the frequency of residual functional LSCs after chemotherapy with cell cycle induction, reflecting biological heterogeneity of AML. Further studies are required to determine if LSC response to cell cycle modifying agents correlates with patient characteristics such as age, cytogenetics, presence of specific mutations and response to prior therapies. In addition, the LSC responsiveness to cell cycle induction itself as a prognostic indicator must be investigated.
Agents that modify cell cycle or disrupt stem cell-niche interactions are also expected to affect normal HSCs. To begin to address this issue, we examined in vivo survival of normal HSCs after Ara-C alone compared with Ara-C following G-CSF in NOD/SCID/IL2rγ null recipients reconstituted with normal human hematopoiesis 25 . We found that the rate of apoptosis in hCD45 + CD34 + CD38 − human HSCs was not significantly increased after cytokine-combined chemotherapy compared with chemotherapy alone (Supplementary Fig. 5 ). These findings are consistent with the lack of excess hematologic toxicity in patients receiving cytokine-combined chemotherapy in previously published clinical studies [17] [18] [19] [20] [21] [22] . More extensive evaluation of the effects of the proposed therapy including long-term repopulation and selfrenewal capacity of human HSCs is required. Normal HSC rescue may be required to optimize the effect of cytokine-combined anti-LSC therapy and to assure patient safety.
In a model of murine leukemia, restriction of cell cycle entry appears to contribute to LSC maintenance, further supporting the l e t t e r s essential role of cell cycle regulation in LSC function 26 . Therefore, agents that promote LSC cell cycle entry and/or disrupt the interactions between LSCs and the bone marrow niche, including modifiers of CXCL12/CXCR4, VLA-4/fibronectin and Groβ/CXCR2 axes, may effectively alter LSC chemotherapy responsiveness [27] [28] [29] . Recently, it was demonstrated that a CXCR4 antagonist mobilizes murine leukemic cell lines and human AML cells 30 . Similarly, mobilization and chemosensitization of murine leukemia with a CXCR4 antagonist has also been shown 31 . In addition, recent studies have elegantly demonstrated that interferon-α induces the proliferation of murine normal HSCs and that the suppression of interferon-α signaling protects murine normal HSCs from exhaustion through the maintenance of cell cycle quiescence 32, 33 . These findings have led to the hypothesis that the mechanism of interferon-α action against CML may be related to its effects on the cell cycle status of CML stem cells 34 . Whether these agents are effective in altering the cell cycle status and chemotherapy responsiveness of LSCs must be investigated in various hematologic malignancies.
Here we demonstrated that functional modification of human primary AML LSCs facilitates their effective elimination in vivo. Recent studies have also demonstrated that cell surface markers expressed on LSCs may be effective targets for anti-LSC therapy [35] [36] [37] . Multifaceted investigational approaches that integrate functional modification of LSCs with discovery of LSC-specific target molecules will be required for the development of effective LSC-targeted therapies for AML.
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